Mitomycin Medac

Mitomycin, the active ingredient in Mitomycin Medac, is a antineoplastic antibiotic (alkylating agent) presented as a sterile powder for reconstitution for intravenous and intravesical use. It is employed in the treatment of several solid tumours, including bladder, gastric, pancreatic, breast and head‑and‑neck cancers.

GNH USA supplies Mitomycin Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Mitomycin is used in oncology to target malignant cells in various solid tumours. - Bladder cancer: intravesical administration aims to reduce tumour recurrence after transurethral resection. - Gastric cancer: intravenous therapy is combined with other agents to improve response rates. - Pancreatic cancer: used as part of combination regimens to enhance cytotoxic effect. - Breast cancer: administered intravenously in advanced disease settings. - Head and neck cancer: incorporated into multimodal chemotherapy protocols.

Mitomycin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring during or after infusion. - Myelosuppression: reduced white blood cells, neutrophils, and platelets. - Fatigue: generalized tiredness often reported during treatment cycles. - Renal toxicity: transient increase in serum creatinine. - Mucositis: inflammation of the oral mucosa.

Serious or Rare Side Effects: - Pulmonary fibrosis: progressive scarring of lung tissue. - Severe hemorrhagic cystitis: painful bladder bleeding. - Hemolytic‑uremic syndrome: acute kidney injury with hemolysis. - Anaphylactic reactions: rare but potentially life‑threatening allergy.

When using Mitomycin, clinicians should observe several safety measures to minimise risks. - Monitor blood counts: perform regular CBC to detect myelosuppression early. - Assess renal function: evaluate serum creatinine before each dose. - Avoid concurrent nephrotoxic drugs: limit use of aminoglycosides and NSAIDs. - Use protective hydration: ensure adequate fluid intake to reduce bladder toxicity. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with specialist. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mitomycin can interact with other medicines, influencing its efficacy or toxicity.

Major Interactions (Avoid): - High‑dose cyclophosphamide: additive bone‑marrow suppression. - Warfarin: increased risk of bleeding due to mucosal injury. - Nephrotoxic antibiotics (e.g., vancomycin): heightened renal toxicity.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., fluconazole): may alter mitomycin metabolism. - NSAIDs: can exacerbate renal impairment. - Radiotherapy: combined use may increase tissue damage.